<DOC>
	<DOC>NCT00741429</DOC>
	<brief_summary>The main purpose of the trial is to evaluate pulmonary function in subjects who had completed any one of the 4 MKC parent trials (MKC-TI-009, MKC-TI-102, MKC-TI-103, or MKC-TI-030) for an additional 2-month safety follow-up.</brief_summary>
	<brief_title>A 2-Month Safety Follow-Up Trial</brief_title>
	<detailed_description>This was a 2-month safety follow-up study of subjects from MannKind protocols MKC-TI-009, MKC-TI-102, MKC-TI-103 and MKC-TI-030. No study medications were administered during this trial. The adverse event data included are for the combined Safety population irrespective of previous treatments in the parent trials.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subjects who have completed any of the 4 MKC parent trials (MKCTI103, MKCTI009, MKCTI102, MKCTI030) Urine cotinine test of less than or equal to 100 ng/mL Written informed consent Subjects who started smoking during the 4 week followup phase of the parent trial Subjects who began a new inhaled insulin regimen with an investigational drug during the 4 week followup phase of the parent trial and/or are participation in another clinical trial Female subjects who are pregnant, lactating or planning on becoming pregnant Subjects with a positive urine drug screening at Visit 1 Female subjects of childbearing potential not practicing adequate birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>